Glofitamab联合Polatuzumab Vedotin治疗难治性伯基特淋巴瘤。

{"title":"Glofitamab联合Polatuzumab Vedotin治疗难治性伯基特淋巴瘤。","authors":"Anca Prica,Mark Roschewski,Peter Beale,Stefania Pittaluga,Jan Delabie,Claudia Ortega,Robert Kridel","doi":"10.1056/nejmc2501018","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"13 1","pages":"1760-1762"},"PeriodicalIF":96.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma.\",\"authors\":\"Anca Prica,Mark Roschewski,Peter Beale,Stefania Pittaluga,Jan Delabie,Claudia Ortega,Robert Kridel\",\"doi\":\"10.1056/nejmc2501018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":54725,\"journal\":{\"name\":\"New England Journal of Medicine\",\"volume\":\"13 1\",\"pages\":\"1760-1762\"},\"PeriodicalIF\":96.2000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New England Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1056/nejmc2501018\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/nejmc2501018","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}